Indobufen (CAS 63610-08-2) Suppliers and Product Information

Indobufen is a platelet aggregation inhibitor related to the anti-inflammatory agent indoprofen. It has shown clinical efficacy in peripheral artery disease, prevention of deep vein thrombosis after myocardial infarction, and in blocking exercise-induced increase in platelet aggregation in angina patients. It is a reversible but very potent inhibitor of platelet COX-1 activity.

Frequently Asked Questions about Indobufen

Q: What is the primary use of Indobufen?

A: Indobufen is primarily used as a platelet aggregation inhibitor and anticoagulant drug. It has anti-inflammatory and ***gesic effects and is used as an antithrombotic agent.

Q: What is the recommended dosage for Indobufen?

A: For the secondary prevention of thromboembolic events, 100 or 200 mg of indobufen twice daily is as effective as warfarin or aspirin in patients with or without atrial fibrillation.

Q: Is Indobufen available worldwide?

A: Currently, indobufen is only available for routine clinical use in Europe.

Q: What are some alternative names for Indobufen?

A: Some synonyms for Indobufen include 1-Oxo-2-(p-(α-ethyl-carboxymethyl)phenyl)isoindoline, 2-(p-1-Oxo-2-isoindolinyl)phenyl butyric acid, and K-2930.